Characterization of the role of EGF-A of low density lipoprotein receptor in PCSK9 binding

被引:54
作者
Gu, Hong-mei [1 ]
Adijiang, Ayinuer [1 ]
Mah, Matthew [1 ]
Zhang, Da-wei [1 ]
机构
[1] Univ Alberta, Dept Pediat & Biochem, Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada
基金
加拿大健康研究院;
关键词
proprotein convertase subtilisin kexin-like 9; epidermal growth factor precursor homology domain A; ligand binding; AUTOSOMAL-DOMINANT HYPERCHOLESTEROLEMIA; LDL RECEPTOR; SECRETED PCSK9; FAMILIAL HYPERCHOLESTEROLEMIA; MOLECULAR CHARACTERIZATION; PLASMA-CHOLESTEROL; LIGAND-BINDING; MICE LACKING; HEPG2; CELLS; DEGRADATION;
D O I
10.1194/jlr.M041129
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Proprotein convertase subtilisin kexin-like 9 (PCSK9) promotes the degradation of low density lipoprotein receptor (LDLR) and plays an important role in regulating plasma LDL-cholesterol levels. We have shown that the epidermal growth factor precursor homology domain A (EGF-A) of the LDLR is critical for PCSK9 binding at the cell surface (pH 7.4). Here, we further characterized the role of EGF-A in binding of PCSK9 to the LDLR. We found that PCSK9 efficiently bound to the LDLR but not to other LDLR family members. Replacement of EGF-A in the very low density lipoprotein receptor (VLDLR) with EGF-A of the LDLR promoted the degradation of the mutant VLDLR induced by PCSK9. Furthermore, we found that PCSK9 bound to recombinant EGF-A in a pH-dependent manner with stronger binding at pH 6.0. We also identified amino acid residues in EGF-A of the LDLR important for PCSK9 binding. Mutations G293H, D299V, L318D, and L318H reduced PCSK9 binding to the LDLR at neutral pH without effect at pH 6.0, while mutations R329P and E332G reduced PCSK9 binding at both pH values. Thus, our findings reveal that EGF-A of the LDLR is critical for PCSK9 binding at the cell surface (neutral pH) and at the acidic endosomal environment (pH 6.0), but different determinants contribute to efficient PCSK9 binding in different pH environments.
引用
收藏
页码:3345 / 3357
页数:13
相关论文
共 49 条
[1]   Mutations in PCSK9 cause autosomal dominant hypercholesterolemia [J].
Abifadel, M ;
Varret, M ;
Rabès, JP ;
Allard, D ;
Ouguerram, K ;
Devillers, M ;
Cruaud, C ;
Benjannet, S ;
Wickham, L ;
Erlich, D ;
Derré, A ;
Villéger, L ;
Farnier, M ;
Beucler, I ;
Bruckert, E ;
Chambaz, J ;
Chanu, B ;
Lecerf, JM ;
Luc, G ;
Moulin, P ;
Weissenbach, J ;
Prat, A ;
Krempf, M ;
Junien, C ;
Seidah, NG ;
Boileau, C .
NATURE GENETICS, 2003, 34 (02) :154-156
[2]   The Molecular Basis of Familial Hypercholesterolemia in Lebanon: Spectrum of LDLR Mutations and Role of PCSK9 as a Modifier Gene [J].
Abifadel, Marianne ;
Rabes, Jean-Pierre ;
Jambart, Selim ;
Halaby, Georges ;
Gannage-Yared, Marie-Helene ;
Sarkis, Antoine ;
Beaino, Ghada ;
Varret, Mathilde ;
Salem, Nabiha ;
Corbani, Sandra ;
Aydenian, Hermine ;
Junien, Claudine ;
Munnich, Arnold ;
Boileau, Catherine .
HUMAN MUTATION, 2009, 30 (07) :E682-E691
[3]   Mutations and Polymorphisms in the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene in Cholesterol Metabolism and Disease [J].
Abifadel, Marianne ;
Rabes, Jean-Pierre ;
Devillers, Martine ;
Munnich, Arnold ;
Erlich, Daniele ;
Junien, Claudine ;
Varret, Mathilde ;
Boileau, Catherine .
HUMAN MUTATION, 2009, 30 (04) :520-529
[4]  
Allard Delphine, 2005, Hum Mutat, V26, P497, DOI 10.1002/humu.9383
[5]   Structural features of the low-density lipoprotein receptor facilitating ligand binding and release [J].
Beglova, N ;
Jeon, H ;
Fisher, C ;
Blacklow, SC .
BIOCHEMICAL SOCIETY TRANSACTIONS, 2004, 32 :721-723
[6]   Cooperation between fixed and low pH-inducible interfaces controls lipoprotein release by the LDL receptor [J].
Beglova, N ;
Jeon, H ;
Fisher, C ;
Blacklow, SC .
MOLECULAR CELL, 2004, 16 (02) :281-292
[7]   Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants [J].
Bottomley, Matthew J. ;
Cirillo, Agostino ;
Orsatti, Laura ;
Ruggeri, Lionello ;
Fisher, Timothy S. ;
Santoro, Joseph C. ;
Cummings, Richard T. ;
Cubbon, Rose M. ;
Lo Surdo, Paola ;
Calzetta, Alessandra ;
Noto, Alessia ;
Baysarowich, Jennifer ;
Mattu, Marco ;
Talamo, Fabio ;
De Francesco, Raffaele ;
Sparrow, Carl P. ;
Sitlani, Ayesha ;
Carfi, Andrea .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (02) :1313-1323
[8]   Effect of mutations in the PCSK9 gene on the cell surface LDL receptors [J].
Cameron, J ;
Holla, OL ;
Ranheim, T ;
Kulseth, MA ;
Berge, KE ;
Leren, TP .
HUMAN MOLECULAR GENETICS, 2006, 15 (09) :1551-1558
[9]   Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9 [J].
Careskey, Holly E. ;
Davis, R. Aleks ;
Alborn, William E. ;
Troutt, Jason S. ;
Cao, Guoqing ;
Konrad, Robert J. .
JOURNAL OF LIPID RESEARCH, 2008, 49 (02) :394-398
[10]   Sequence variations in PCSK9, low LDL, and protection against coronary heart disease [J].
Cohen, JC ;
Boerwinkle, E ;
Mosley, TH ;
Hobbs, HH .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (12) :1264-1272